iSpecimen Inc. Revenue
iSpecimen Inc. (ISPC) reported Revenue of $151.94 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-14
- iSpecimen Inc. revenues for the quarter ending 2026-06-30 was $151.94K, a 78.69% decline year-over-year.
- iSpecimen Inc. revenues for the quarter ending 2026-03-31 was $156.01K, a 85.25% decline year-over-year.
- iSpecimen Inc. revenues for the quarter ending 2025-12-31 was $51.76K, a 96.49% decline year-over-year.
- iSpecimen Inc. revenues for the quarter ending 2025-09-30 was $106.59K, a 96.00% decline year-over-year.
- iSpecimen Inc. revenues for fiscal 2025 was $1.93M, a 79.24% decline from fiscal 2024.
- iSpecimen Inc. revenues for fiscal 2024 was $9.29M, a 6.42% decline from fiscal 2023.
- iSpecimen Inc. revenues for fiscal 2023 was $9.93M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.94K 10-Q · filed 2026-08-14 | $307.95K 10-Q · filed 2026-08-14 | $359.71K derived: sum of 3 quarters · filed 2026-08-14 | $466.30K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $156.01K 10-Q · filed 2026-05-18 | $207.77K derived: sum of 2 quarters · filed 2026-05-18 | $314.36K derived: sum of 3 quarters · filed 2026-05-18 | $1.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $51.76K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $158.35K derived: sum of 2 quarters · filed 2026-04-01 | $871.49K derived: sum of 3 quarters · filed 2026-08-14 | $1.93M 10-K · filed 2026-04-01 |
| 2025-09-30 | $106.59K 10-Q · filed 2025-11-17 | $819.73K derived: sum of 2 quarters · filed 2026-08-14 | $1.88M 10-Q · filed 2025-11-17 | $3.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $713.13K 10-Q · filed 2026-08-14 | $1.77M 10-Q · filed 2026-08-14 | $3.25M derived: sum of 3 quarters · filed 2026-08-14 | $5.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-18 | $2.53M derived: sum of 2 quarters · filed 2026-05-18 | $5.19M derived: sum of 3 quarters · filed 2026-05-18 | $8.06M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $4.14M derived: sum of 2 quarters · filed 2026-04-01 | $7.00M derived: sum of 3 quarters · filed 2026-04-01 | $9.29M 10-K · filed 2026-04-01 |
| 2024-09-30 | $2.66M 10-Q · filed 2025-11-17 | $5.53M derived: sum of 2 quarters · filed 2025-11-17 | $7.82M 10-Q · filed 2025-11-17 | |
| 2024-06-30 | $2.86M 10-Q · filed 2025-08-14 | $5.15M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $2.29M 10-Q · filed 2025-05-19 | |||
| 2023-12-31 | $9.93M 10-K · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |